Apath, LLC is a privately held pharmaceutical development services company with a focus on hepatitis C virus (HCV) and other human viral pathogens.  Apath was founded in St. Louis, Missouri, by Charles M. Rice, Ph.D., Professor of Molecular Microbiology, Rockefeller University and Washington University School of Medicine.

MISSION:

Apath is engaged in the commercial application of virology and viral genetics to assist pharmaceutical companies in discovering and developing therapeutic products for the treatment of viral infections.    Apath’s primary focus is on RNA viruses.  RNA viruses account for the majority of viruses which are human pathogens.  In addition to HCV, they include several medically important viruses – Influenza, Respiratory Syncytial Virus (RSV), and Hemorrhagic Fever Viruses.   

CAPABILITIES:

Apath's founder and key employees have a proven track record and comprehensive expertise in virology and molecular biology. Apath has key patents, proprietary know-how, and license agreements related to hepatitis C virus (HCV) and other important human viral pathogens and methods to detect viruses.  In addition, Apath has a proprietary antiviral screening platform (patent pending).